Holen Sie sich die Stockscreener-App
788.04
1.00%
-7.98
Vorhandelsmarkt:
788.83
0.79
+0.10%
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Analysts Are Bullish on Top Healthcare Stocks: Agilent (A), Regeneron (REGN) - The Globe and Mail
REGN LAWSUIT ALERT: Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. InvestorsLead Plaintiff Deadline September 14, 2026 - ACCESS Newswire
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
REGENXBIO reports three-year ALTITUDE DRSS data - Mugglehead Investment Magazine
Regeneron stock last at USD 792.19, down 1.20 percent in New York trading - AD HOC NEWS
Regeneron Pharmaceuticals, Inc. (REGN) latest stock news and headlines - Yahoo Finance UK
Did You Lose Money on Regeneron Pharmaceuticals, Inc. (REGN)? Levi & Korsinsky Urges Investors to Act Before September 14, 2026 - accessnewswire.com
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026 - Investing News Network
Regeneron Approaching Incremental Catalysts Like Upcoming Olatorepatide Data Readout, RBC Says - marketscreener.com
Regeneron (REGN) Stock Still Looks Undervalued After A 40% Run - Yahoo Finance
Regeneron Pharmaceuticals (REGN) Could Be 4% Undervalued Following Class Action Filing - simplywall.st
Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts - MarketBeat
Regeneron at Bernstein healthcare forum: growth engines stay in focus - Investing.com India
Regeneron Pharmaceuticals, Inc. at Bernstein Insights Healthcare Leaders and Disruptors Transcript - GuruFocus
State Street Corp Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals stock trades near its yearly high - AD HOC NEWS
Why is Regeneron Pharmaceuticals (NASDAQ:REGN) back on investors' radar? - Kalkine Media
Is Regeneron Stock a Bargain Below $800? - The Motley Fool
Is Regeneron Stock a Bargain Below $800? - The Motley Fool
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Andra AP fonden - MarketBeat
Regeneron stock gains 1.67 percent as legal risk eases - ad-hoc-news.de
Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years - Benzinga
Regeneron, Bayer Hit Back In Eye Med Biosimilar Clash - Law360
Regeneron Pharmaceuticals stock holds near its yearly range - AD HOC NEWS
REGN Watch: What Regeneron Pharmaceuticals's Latest Moves Mean for Healthcare Stocks Investors - Kalkine Media
Regeneron stock heads into the open after a 1.7 percent gain - AD HOC NEWS
Regeneron Investors Can't Use FCA Action To Support Suit - Law360
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Regeneron stock gains as legal risk eases and dividend profile stands out - AD HOC NEWS
Regeneron Beats Investor Suit Over Medicare Drug Price Reporting - Bloomberg Government News
Regeneron stock heads into the open after a 0.4 percent gain - AD HOC NEWS
Regeneron stock gains analyst support after strong quarterly figures - AD HOC NEWS
Nykredit A S Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) Options Chain - Yahoo! Finance Canada
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded by Wall Street Zen to Strong-Buy Rating - MarketBeat
Why Regeneron Pharmaceuticals (NASDAQ:REGN) Is Back in Focus? - Kalkine Media
Corient Private Wealth LP Sells 5,600 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
How Investors Are Reacting To Regeneron Pharmaceuticals Stock (REGN) Trial Disclosure Lawsuits - simplywall.st
Integrated Wealth Concepts LLC Reduces Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bank of America Corp DE Purchases 101,469 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Is Regeneron Pharmaceuticals (REGN) Still Undervalued After The Class Action Lawsuits? - simplywall.st
Will Fianlimab-Libtayo Trial Misstatement Lawsuits Change Regeneron Pharmaceuticals' (REGN) Pipeline-Driven Narrative? - Yahoo Finance
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
WINTON GROUP Ltd Sells 12,978 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - mykxlg.com
REGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds - The National Law Review
REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - PR Newswire
REGN 2-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Invest - The National Law Review
REGN 2-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. - GlobeNewswire
Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth - Yahoo Finance
Is Regeneron (NASDAQ:REGN) Entering A New Phase? - Kalkine Media
INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. (REGN) Investo - The National Law Review
Regeneron stock dips ahead of class action deadline - ad-hoc-news.de
REGN SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regeneron I - The National Law Review
MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Why Is Regeneron Pharmaceuticals (REGN) Facing A New Investor Lawsuit? - simplywall.st
National Pension Service Acquires 8,264 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron stock heads into the open after a 1.8 percent drop - ad-hoc-news.de
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - FinancialContent
Best Biotech Stocks To Add to Your WatchlistSeptember 10th - MarketBeat
2.08%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):